Cargando…

A pandemic-enabled comparison of discovery platforms demonstrates a naïve antibody library can match the best immune-sourced antibodies

As a result of the SARS-CoV-2 pandemic numerous scientific groups have generated antibodies against a single target: the CoV-2 spike antigen. This has provided an unprecedented opportunity to compare the efficacy of different methods and the specificities and qualities of the antibodies generated by...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrara, Fortunato, Erasmus, M. Frank, D’Angelo, Sara, Leal-Lopes, Camila, Teixeira, André A., Choudhary, Alok, Honnen, William, Calianese, David, Huang, Deli, Peng, Linghan, Voss, James E., Nemazee, David, Burton, Dennis R., Pinter, Abraham, Bradbury, Andrew R. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786865/
https://www.ncbi.nlm.nih.gov/pubmed/35075126
http://dx.doi.org/10.1038/s41467-021-27799-z
Descripción
Sumario:As a result of the SARS-CoV-2 pandemic numerous scientific groups have generated antibodies against a single target: the CoV-2 spike antigen. This has provided an unprecedented opportunity to compare the efficacy of different methods and the specificities and qualities of the antibodies generated by those methods. Generally, the most potent neutralizing antibodies have been generated from convalescent patients and immunized animals, with non-immune phage libraries usually yielding significantly less potent antibodies. Here, we show that it is possible to generate ultra-potent (IC(50) < 2 ng/ml) human neutralizing antibodies directly from a unique semisynthetic naïve antibody library format with affinities, developability properties and neutralization activities comparable to the best from hyperimmune sources. This demonstrates that appropriately designed and constructed naïve antibody libraries can effectively compete with immunization to directly provide therapeutic antibodies against a viral pathogen, without the need for immune sources or downstream optimization.